Cor Therapeutics Inc. (CORR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: RCMac who wrote (662)	4/17/2001 10:26:50 AM
From: tuck	Read Replies (1) of 712

Where is everybody? COR makes its numbers: >>COR Therapeutics posts 1st-qtr loss, sees profit for year SOUTH SAN FRANCISCO, Calif., April 17 (Reuters) - Drug developer COR Therapeutics (NasdaqNM:CORR - news) on Tuesday reported a first quarter loss of 5 cents per share but said sales its blood clotting inhibitor treatment Integrilin would help drive the firm to profitability for the full year. The biotechnology company posted a loss of $2.86 million, or 5 cents per share, compared with a loss of $9.94 million, or 19 cents, in the year-ago quarter. Analysts on average had expected the company would lose 6 cents per share, with analysts' estimates ranging between a loss of 5 cents and 6 cents per share, according to research firm Thomson Financial/First Call. COR reaffirmed estimates that placed 2001 earnings per share between 35 cents and 37 cents per share, just above the First Call consensus of a profit of 34 cents per share. The company estimated global sales of Integrilin of between $245 million and $260 million for the year. Sales of Integrilin as reported to COR by marketing partner Schering-Plough Corp. (NYSE:SGP - news) were $38.1 million for the first quarter.<< Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next